Sterile injectable suspension remains the dominant dosage configuration for inactivated *Erysipelothrix rhusiopathiae* bacterin antigen across commercial swine production systems in the EU, North America, and Southeast Asia. The bulk aqueous antigen concentrate—typically standardized to a relative potency of 2.0–5.0 IU per dose following inactivation with 0.2–0.5% v/v formaldehyde at 37°C for 24–72 h—is blended with sterile aluminum hydroxide gel adjuvant at 10–30% v/v final concentration under aseptic conditions. Final pH is adjusted to 6.5–7.2 using 0.1 M sodium hydroxide or hydrochloric acid, and the suspension is homogenized through a high-shear mixer operating at 3,000–5,000 rpm for 15–30 min to achieve uniform adjuvant–antigen adsorption. Resuspendability after settling is a critical quality attribute: the sediment formed during 2–8°C storage must redisperse within 30 s of manual shaking, and the homogeneity of the redispersed suspension is verified per Ph. Eur. 2.9.5 uniformity of mass of delivered doses from multidose containers. Syringeability testing through 18G and 21G needles at 5°C and 25°C confirms acceptable injection force and absence of needle clogging across the claimed shelf life. Sterility testing is performed per Ph. Eur. 2.6.1 using membrane filtration or direct inoculation, and freedom from mycoplasma contamination is demonstrated per Ph. Eur. 2.6.7. Potency is evaluated by the mouse protection test described in Ph. Eur. monograph 0064 and USDA 9 CFR 113.119, in which vaccinated mice are challenged with a virulent strain of *Erysipelothrix rhusiopathiae* serotype 2; survival of at least 80% of vaccinated animals versus ≤20% of unvaccinated controls is the acceptance criterion. Preservative selection is constrained by compatibility with aluminum hydroxide gel: thiomersal at 0.005–0.01% w/v is widely used, although formulations destined for export to markets with mercury restrictions may substitute 2-phenoxyethanol at 0.5% v/v. Batch-to-batch variance in antigen adsorption efficiency—measured by residual unbound protein in the supernatant via Bradford or bicinchoninic acid assay—must remain within ±10% of the reference batch to ensure consistent immune stimulation.

Can Inactivated Bacterin Antigen Survive Feed-Matrix Thermal Processing for Oral Premix Delivery?

The adaptation of inactivated Erysipelothrix rhusiopathiae bacterin antigen to oral premix, granule, or drinking-water soluble powder formats presents a fundamentally different set of formulation constraints compared with parenteral delivery. The primary technical barrier is gastric proteolysis coupled with pH-mediated denaturation: antigenic surface proteins, particularly the SpaA adhesion protein and the 64–66 kDa protective surface proteins of serotype 2 strains, undergo irreversible conformational loss at gastric pH below 3.0 and are susceptible to pepsin cleavage within 15–30 min of exposure. Consequently, direct addition of uncoated antigen concentrate to feed premix is not a viable route for immune priming; formulations must incorporate enteric protection. Spray-dried microparticles using methacrylic acid copolymer dispersion (Eudragit L30 D-55, dissolution threshold pH 5.5) applied at 20–30% w/w coating level onto antigen-loaded sucrose or trehalose cores have been evaluated in published feasibility studies, though commercial products using this configuration for inactivated erysipelas bacterin are limited. The carrier system for active premix dilution—typically spray-dried lactose, microcrystalline cellulose, or calcium carbonate—must maintain blend uniformity within a coefficient of variation of ≤5.0% as specified in EU Regulation (EC) No 183/2005 Annex II for medicated feed ingredients. When granular dosage forms are prepared by low-shear wet granulation, the binder solution must be applied at ≤40°C to avoid thermal inactivation of the antigen; published stability data for Erysipelothrix bacterin antigen indicate loss of protective efficacy is detectable after 60 min at 50°C and after 10 min at 60°C in aqueous suspension. Moisture sensitivity of the final oral product requires primary packaging with desiccant when ambient relative humidity exceeds 60% RH, as moisture uptake above 5% w/w in the premix carrier can induce particle agglomeration and non-uniform dosing in trough-water delivery systems. For drinking-water soluble powder applications, dispersibility in hard water containing 200–400 mg/L calcium carbonate equivalent must be confirmed, and reconstituted solution stability must be maintained for at least 24 h at 15–25°C to accommodate on-farm water medicator reservoirs. The regulatory pathway for oral inactivated erysipelas vaccines diverges from parenteral monographs: an application dossier must include target animal safety and efficacy studies conducted specifically by the oral route, and VICH GL44 stability requirements apply to the medicated premix as a finished dosage form.

Lyophilization Cycle Parameters for Antigenic Mass Preservation in Powder Formats

A lyophilization cycle developed for inactivated Erysipelothrix rhusiopathiae bacterin antigen must maintain the conformational integrity of surface protein antigens while achieving residual moisture low enough to ensure room-temperature or refrigerated long-term stability. The frozen formulation glass transition temperature (Tg′) of the maximally cryoconcentrated solution governs primary drying temperature selection: for formulations containing sucrose or trehalose at 5–10% w/v as lyoprotectants, Tg′ values typically fall between −34°C and −28°C, and primary drying must be executed at product temperatures 3–5°C below Tg′ to prevent cake collapse. A representative cycle profile includes freezing to −45°C at 0.5°C/min, annealing at −20°C for 2–4 h to facilitate complete ice crystallization, primary drying at −30°C to −25°C under 80–150 mTorr chamber pressure for 24–48 h, and secondary drying at 25°C for 6–12 h. Residual moisture in the finished lyophilized cake is specified at ≤3.0% w/w via Karl Fischer titration; above this threshold, molecular mobility increases and antigen aggregation becomes detectable in accelerated stability studies at 37°C/75% RH within 4 weeks. Cake appearance criteria include absence of meltback, uniform color (white to off-white), and complete reconstitution within 2 min after addition of water for injection at 15–25°C. For veterinary clinic reconstitution, the lyophilized powder is reconstituted with sterile diluent to a final suspension volume of 2 mL or 5 mL per dose, and the reconstituted product must meet the same resuspendability and syringeability criteria as ready-to-use injectable suspensions. Process validation for lyophilized bacterin powder requires demonstration of batch-to-batch cake temperature uniformity: product temperature thermocouples placed in corner and center vial positions must record a temperature spread of ≤2°C throughout primary drying to preclude edge-vial collapse or incomplete drying.

Table 1. Compliance test matrix for inactivated swine erysipelas vaccine injectable suspension per Ph. Eur. monograph 0064 and referenced general chapters

Quality Attribute	Test Method	Acceptance Criterion	Frequency
Sterility	Ph. Eur. 2.6.1	No growth after 14 d incubation	Each batch
Potency (mouse protection)	Ph. Eur. 0064 / USDA 9 CFR 113.119	≥80% survival in vaccinated mice vs ≤20% in controls	Each batch
Inactivation completeness	Culture of inactivated bulk	No growth on blood agar or in thioglycollate broth after 7 d	Each bulk lot
pH	Ph. Eur. 2.2.3	6.5–7.2	Each batch
Homogeneity of delivered dose	Ph. Eur. 2.9.5	CV ≤ 5% across 10 delivered doses	Each batch
Preservative content	HPLC (thiomersal) or GC (2-phenoxyethanol)	90–110% of label claim	Each batch
Residual formaldehyde	Ph. Eur. 2.4.18	≤0.5 mg/mL final product	Each batch
Abnormal toxicity	USDA 9 CFR 113.38	No adverse reaction in mice or guinea pigs over 7 d	Each batch

Adjuvant Adsorption Capacity and Multivalent Co-Formulation Limits

Aluminum hydroxide gel exhibits a finite protein adsorption capacity of approximately 0.5–2.0 mg protein per mg aluminum depending on the isoelectric point of the antigen, the ionic strength of the formulation buffer, and the presence of competing phosphate anions. For Erysipelothrix rhusiopathiae bacterin antigen—whose protective surface proteins carry a net negative charge at formulation pH 6.5–7.2—electrostatic adsorption onto the positively charged aluminum hydroxide gel surface is efficient and saturable. When the inactivated erysipelas antigen is co-formulated with other swine vaccine antigens in multivalent products, competitive binding at the adjuvant surface becomes a formulation risk that is resolved by sequential antigen addition during compounding: the antigen with the highest isoelectric point or lowest electrostatic affinity is adsorbed first, followed by equilibration for 30–60 min at 15–25°C before addition of the second antigen. In combination vaccines containing inactivated erysipelas bacterin with porcine parvovirus and Leptospira interrogans antigens—a configuration approved under USDA 9 CFR 113.101 and 113.102 for parvovirus and 113.103 for Leptospira—the total protein load on the adjuvant must be verified by residual unbound protein assay after each antigen addition, with a target of ≥85% adsorption efficiency. Phosphate-buffered saline at concentrations exceeding 10 mM is avoided in the final formulation because phosphate anions displace adsorbed antigen from aluminum hydroxide gel by ligand exchange, as documented in vaccine adjuvant literature. The addition of mineral oil–based or squalene-based emulsion adjuvants is generally not practiced for swine erysipelas bacterins due to injection-site reaction concerns and the absence of regulatory precedent in the EU dossier framework; aluminum-based adjuvants remain the reference standard for this antigen.

Using Sow Vaccination Timing to Offset Maternal Antibody Interference in Nursery Pigs

Maternal antibody titers in piglets born to sows vaccinated with inactivated Erysipelothrix rhusiopathiae bacterin follow a predictable decay curve that directly influences the timing of active immunization in nursery and grower pigs. Sows are typically revaccinated at 3–4 weeks before farrowing to maximize colostral antibody transfer; passive immunoglobulin G specific to erysipelas protective antigens is absorbed by the neonatal piglet during the first 24–48 h of life via the open gut, with peak serum titers reached by 72 h postpartum. The half-life of maternally derived erysipelas antibody in piglet serum is reported in published field studies to be approximately 14–21 days, rendering early vaccination before 8 weeks of age ineffective due to neutralization of the inactivated antigen before a primary immune response can be generated. Serological monitoring using an ELISA targeting the SpaA antigen or a whole-cell antigen preparation is recommended to map the herd-specific decay curve; when maternal antibody titers fall below an optical density ratio of 0.3–0.5 relative to a positive control serum, active vaccination becomes immunologically feasible. In farrow-to-finish operations, this typically corresponds to 8–12 weeks of age, with a booster dose administered 3–4 weeks later. The booster response is characterized by an anamnestic IgG rise that is measurable within 7–10 days post-booster and protects through the finishing phase, during which the risk of clinical erysipelas—diamond skin lesions, acute septicemia, and chronic arthritis—is highest in pigs approaching market weight. Breeding herd vaccination protocols call for semiannual revaccination of sows and boars, with the second annual dose ideally timed to coincide with the pre-farrowing window for the subsequent parity.

Compressing Lyophilized Bacterin Antigen into Enteric-Coated Oral Dosage Forms

The compression of lyophilized Erysipelothrix rhusiopathiae bacterin antigen into tablet or capsule dosage forms for oral administration to swine requires excipient systems that preserve antigenic mass during the mechanical and thermal stresses of compression while ensuring gastric protection and controlled release in the small intestine. Direct compression is the preferred manufacturing route because wet granulation would expose the antigen to elevated moisture and drying temperatures incompatible with antigenic stability. A placebo-excipient matrix of microcrystalline cellulose (PH-102 grade, particle size 90–150 μm) combined with spray-dried lactose at a 50:50 ratio provides adequate compressibility at tablet hardness of 5–8 kp, and croscarmellose sodium at 2–4% w/w functions as a superdisintegrant for rapid release once the enteric coat dissolves. The enteric coating system—applied by pan coating to a weight gain of 8–12% w/w—must demonstrate acid resistance per Ph. Eur. 2.9.1 dissolution testing in 0.1 M hydrochloric acid for 2 h (no disintegration, less than 10% antigen release) followed by rapid release in phosphate buffer at pH 6.8 within 45 min. Capsule formulations bypass some compression-related shear stress but require enteric-coated capsules (hydroxypropyl methylcellulose phthalate or cellulose acetate phthalate) to achieve the same gastric resistance profile. For both tablet and capsule formats, published data for this specific configuration using inactivated Erysipelothrix rhusiopathiae bacterin antigen is limited; the technical feasibility has been demonstrated in proof-of-concept studies using model protein antigens, but no commercial oral tablet or capsule product based on inactivated erysipelas bacterin has been registered in the EU or US markets as of the current regulatory landscape. The absence of a registered oral tablet formulation does not reflect insurmountable technical barriers but rather the practical economic constraint that parenteral vaccination delivers more consistent seroconversion rates at lower cost per dose in commercial swine operations. Formulation scientists evaluating this route must additionally address dose uniformity across tablet weight ranges of 500–800 mg in piglets weighing 10–25 kg, where gastric transit time and intestinal pH vary significantly with feeding status.